Combined effects of interferon-α2a and 13-cis-retinoic acid on human melanoma cell growth and stat protein expression

Melanoma Research

Volumn 8, Issue 1, 1998, Pages 31-38

  Bearzatto, A ^a   Orlandi, L ^a   Silvestrini, R ^a   Belli, F ^a   Cascinelli, N ^a   Zaffaroni, N ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cell growth; Interferon; Melanoma cells; Retinoic acid; STAT proteins

Indexed keywords

ISOTRETINOIN; RECOMBINANT ALPHA2A INTERFERON; STAT PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOREGULATION; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CELL COUNT; CELL CYCLE; CELL DIVISION; DNA-BINDING PROTEINS; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; INTERFERON ALFA-2A; ISOTRETINOIN; MELANOMA; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0031916399     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199802000-00006     Document Type: Article

References (24)

1. Kirkwood IM, Ernstoff MS. Role of interferons in the therapy of melanoma. J Invest Dermatol 1990; 95: 180-184.
2. Lotan R, Hendrix MJC, Lippman SC. Retinoids in the management of melanoma. In: Marks R, ed. Retinoids in Cutaneous Malignancy. Oxford: Blackwell Scientific Publication, 1991: 133-149.
3. Kirkwood JM, Ernstoff MS. Cutaneous melanoma. In: De Vita VT, Helman S, Rosemberg SA, eds. Biologic Therapy of Cancer. Philadelphia: JB Lippincott, 1991: 311-333.
4. Sheridan E, Hancock BW. Systemic treatment of metastatic malignant melanoma. In: Kirkham N, Cotton DWK, Lallemand RC, White JE, Rosin RD, eds. Diagnosis and Management of Melanoma in Clinical Practice. London: Springer-Verlag, 1992: 135-152.
5. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996; 14:7-17.
6. Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents. Part I. Cancer Treat Rep 1987; 71: 391-405.
7. Levine N, Meyskens FL, Jr. Topical vitamin A-acid therapy for cutaneous metastatic melanoma, Lancet 1980; ii: 224-226.
8. Modiano M, Dalton W, Lippman S, et al. Phase II study of fenretinide (n-[4-hydroxyphenyl]retinide) in advanced breast cancer and melanoma. Infest New Drugs 1990; 8: 317-319.
9. Frey JR, Peck R, Bollag W Antiproliferative activity of retinoids, interferon a and their combination in five human transformed cell lines. Cancer Lett 1991; 57: 223-227.
10. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-Retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84: 235-241.
11. Lippman SM, Kavanagh JJ, Parades-Espinoza M, et al. 13-cis-T-Retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241-245.
12. Kudelka AP, Freedman RS, Edwards CL, et al. Metastatic adenocarcinoma of the endometrium treated with 13-cis-retinoic acid plus interferon-α. Anticancer Drugs 1993; 4: 335-337.
13. Zupi G, Mauro F, Balduzzi MA, et al. Established melanoma cell lines from different metastatic nodules of a single patient, a useful model for cancer therapy. Proc Am Assoc Cancer Res 1985; 26: 22.
14. Greco C, Zupi G. Biological features and in vitro chemosensitivity of a new model of human melanoma. Anticancer Res 1987; 7: 839.
15. Villa R, Zaffaroni N, Orlandi L, et al. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells. Eur J Cancer 1994; 30A: 1534-1540.
16. Widschwendter M, Daxenbichler G, Bachmair F, et al. Interaction of retinoic acid and interferon-α in breast cancer cell lines. Anticancer Res 1996; 16: 369-374.
17. Schaber B, Mayer P, Schreiner T, et al. Anti-proliferative activity of natural interferon-alpha, isotretinoin and their combination varies in different human melanoma cell lines. Melanoma Res 1994; 4: 321-326.
18. Drewinko B, Loo TI., Brown B, et al. Combination chemotherapy in vitro with adriamycin. Observation of additive, antagonist, and synergistic effect when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys 1976; 1: 187-195.
19. Novick D, Cohen B, Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 1994; 77: 391-400.
20. Abramovich C, Chebath J, Revel M. The human interferon α-receptor protein confers differential responses to human interferon-β versus interferon-α subtypes in mouse and hamster cell transfectants. Cytokine 1994; 6: 414-424.
21. Petkovich M. Regulation of gene expression by vitamin A: the role of nuclear retinoic acid receptors. Anna Rev Nutr 1992; 12: 443-471.
22. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
23. Boylan JF, Gudas LJ. Overexpression of the cellular retinoic and binding protein-I (CRABP-I) results in a reduction in differentiation specific gene expression in F9 teratocarcinoma cells. J Cell Biol 1991; 112: 965-979.
24. Triozzi PL, Walker MJ, Pellegrini AE, et al. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest 1996; 14: 293-298.